249 related articles for article (PubMed ID: 8548933)
1. The Birmingham pituitary database: auditing the outcome of the treatment of acromegaly.
Jenkins D; O'Brien I; Johnson A; Shakespear R; Sheppard MC; Stewart PM
Clin Endocrinol (Oxf); 1995 Nov; 43(5):517-22. PubMed ID: 8548933
[TBL] [Abstract][Full Text] [Related]
2. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure?
Costa AC; Rossi A; Martinelli CE; Machado HR; Moreira AC
J Clin Endocrinol Metab; 2002 Jul; 87(7):3142-7. PubMed ID: 12107214
[TBL] [Abstract][Full Text] [Related]
3. The outcome of surgery for acromegaly: the need for a specialist pituitary surgeon for all types of growth hormone (GH) secreting adenoma.
Lissett CA; Peacey SR; Laing I; Tetlow L; Davis JR; Shalet SM
Clin Endocrinol (Oxf); 1998 Nov; 49(5):653-7. PubMed ID: 10197082
[TBL] [Abstract][Full Text] [Related]
4. Relationships between insulin-like growth factor-1 levels and growth hormone concentrations during diurnal profiles and following oral glucose in acromegaly.
Dobrashian RD; O'Halloran DJ; Hunt A; Beardwell CG; Shalet SM
Clin Endocrinol (Oxf); 1993 Jun; 38(6):589-93. PubMed ID: 8334745
[TBL] [Abstract][Full Text] [Related]
5. Acromegaly.
Scacchi M; Cavagnini F
Pituitary; 2006; 9(4):297-303. PubMed ID: 17077948
[TBL] [Abstract][Full Text] [Related]
6. Factors determining the long-term outcome of surgery for acromegaly.
Osman IA; James RA; Chatterjee S; Mathias D; Kendall-Taylor P
QJM; 1994 Oct; 87(10):617-23. PubMed ID: 7987657
[TBL] [Abstract][Full Text] [Related]
7. Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure?
Damjanovic SS; Neskovic AN; Petakov MS; Popovic V; Macut D; Vukojevic P; Joksimovic MM
Clin Endocrinol (Oxf); 2005 Apr; 62(4):410-7. PubMed ID: 15807870
[TBL] [Abstract][Full Text] [Related]
8. The relationship between 24-hour growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy.
Peacey SR; Toogood AA; Veldhuis JD; Thorner MO; Shalet SM
J Clin Endocrinol Metab; 2001 Jan; 86(1):259-66. PubMed ID: 11232010
[TBL] [Abstract][Full Text] [Related]
9. Clinical, hormonal and magnetic resonance imaging (MRI) predictors of transsphenoidal surgery outcome in acromegaly.
Bourdelot A; Coste J; Hazebroucq V; Gaillard S; Cazabat L; Bertagna X; Bertherat J
Eur J Endocrinol; 2004 Jun; 150(6):763-71. PubMed ID: 15191345
[TBL] [Abstract][Full Text] [Related]
10. Characterization of 24-hour growth hormone secretion in acromegaly: implications for diagnosis and therapy.
Ho KY; Weissberger AJ
Clin Endocrinol (Oxf); 1994 Jul; 41(1):75-83. PubMed ID: 8050134
[TBL] [Abstract][Full Text] [Related]
11. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'.
Nomikos P; Buchfelder M; Fahlbusch R
Eur J Endocrinol; 2005 Mar; 152(3):379-87. PubMed ID: 15757854
[TBL] [Abstract][Full Text] [Related]
12. Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure.
Sheaves R; Jenkins P; Blackburn P; Huneidi AH; Afshar F; Medbak S; Grossman AB; Besser GM; Wass JA
Clin Endocrinol (Oxf); 1996 Oct; 45(4):407-13. PubMed ID: 8959078
[TBL] [Abstract][Full Text] [Related]
13. An audit of treatment outcome in acromegalic patients attending our center at Bergamo, Italy.
Attanasio R; Montini M; Valota M; Cortesi L; Barbò R; Biroli F; Tonnarelli G; Albizzi M; Testa RM; Pagani G
Pituitary; 2008; 11(1):1-11. PubMed ID: 17690987
[TBL] [Abstract][Full Text] [Related]
14. The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly.
Carmichael JD; Bonert VS; Mirocha JM; Melmed S
J Clin Endocrinol Metab; 2009 Feb; 94(2):523-7. PubMed ID: 19033371
[TBL] [Abstract][Full Text] [Related]
15. Assessment of GH status in acromegaly using serum growth hormone, serum insulin-like growth factor-1 and urinary growth hormone excretion.
Bates AS; Evans AJ; Jones P; Clayton RN
Clin Endocrinol (Oxf); 1995 Apr; 42(4):417-23. PubMed ID: 7750196
[TBL] [Abstract][Full Text] [Related]
16. Preoperative growth hormone response to thyrotropin-releasing hormone and oral glucose tolerance test in acromegaly: a retrospective evaluation of 50 patients.
De Marinis L; Mancini A; Bianchi A; Gentilella R; Valle D; Giampietro A; Zuppi P; Anile C; Maira G; Giustina A
Metabolism; 2002 May; 51(5):616-21. PubMed ID: 11979395
[TBL] [Abstract][Full Text] [Related]
17. Effect of acute pharmacological modulation of plasma free fatty acids on GH secretion in acromegalic patients.
Cordido F; Peñalva A; Martinez T; Casanueva FF; Dieguez C
Clin Endocrinol (Oxf); 2001 Apr; 54(4):509-13. PubMed ID: 11318787
[TBL] [Abstract][Full Text] [Related]
18. Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR.
Jenkins PJ; Emery M; Howling SJ; Evanson J; Besser GM; Monson JP
Horm Res; 2004; 62(5):227-32. PubMed ID: 15477693
[TBL] [Abstract][Full Text] [Related]
19. Recent primary transnasal surgical outcomes associated with intraoperative growth hormone measurement in acromegaly.
Abe T; Lüdecke DK
Clin Endocrinol (Oxf); 1999 Jan; 50(1):27-35. PubMed ID: 10341853
[TBL] [Abstract][Full Text] [Related]
20. Body mass index and insulin-like growth factor 1 as risk factors for discordant growth hormone and insulin-like growth factor 1 levels following pituitary surgery in acromegaly.
Zhang S; Li Y; Guo X; Gao L; Lian W; Yao Y; Feng M; Bao X; Wang R; Xing B
J Formos Med Assoc; 2018 Jan; 117(1):34-41. PubMed ID: 28341329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]